respondents for anticipatory N&V in the first two choices. 22% of respondents had no access to clinical psychology services. Half of all respondents thought N&V developed in >25% of patients on MTX and 2/3 of respondents thought 10% or more of patients were switched to biologics because of MTX intolerance rather than inefficacy. Conclusion: MTX-related N&V is recognized as a common problem amongst prescribers of MTX for JIA. Prophylactic strategies such as anti-emetics are variably used, and there are several different strategies followed to manage the problem. This survey's results will support the development of prospective studies comparing different strategies of preventing and dealing with MTX-related N&V. Disclosure statement: The authors have declared no conflicts of interest.
Introduction: Benign joint hypermobility syndrome (BJHS) is a common heritable connective tissue disorder characterized by excessive joint flexibility and musculoskeletal pain. In childhood, BJHS has been linked clinically with disorders of motor control, however the association remains poorly characterized and the extent to which this reflects developmental variation remains uncertain Aims: This study examines data from an interventional study of BJHS in childhood to assess the relationship between joint hypermobility and motor control Method: The study subjects included 117 children between the ages of 5 and 16 years. All had documented joint hypermobility (assessed by a paediatric rheumatologist) and musculoskeletal pain. Motor ability was assessed using the norm-referenced Movement Assessment Battery for Children (M-ABC). The M-ABC includes tests for manual dexterity, ball skills and balance. Children with age-corrected scores falling below the 15th percentile were defined as having movement difficulty. Results: Among the children with BJHS that were assessed, 32% scored 15 percentile on the M-ABC (P < 0.001). The prevalence of movement difficulty was higher in younger when compared with older children with BJHS (5 to 8 years ¼ 41%; 9 to 12 years: 29%; 13 to 16: 19%). Movement difficulty was more common in males (40%) than females (25%). There was no association with the extent of hypermobility as assessed on the Beighton score or with the level of pain as assessed by VAS. Conclusion: Movement difficulty is a common independent component of BJHS in childhood. An assessment of motor function needs to be included as part of the assessment of all children with BJHS and may merit targeted intervention. Introduction: Neuropsychiatric SLE (NPSLE) is a diagnostically challenging, severe, and life-threatening condition. Neuroimaging techniques such as MRI are increasingly used to assist the diagnosis and monitoring of the disease course in adults with NPSLE. The role of MRI in the evaluation of children and adolescents with suspected juvenile NPSLE is however unknown.
Aims: The aim of this study was to describe the abnormalities identified with conventional MRI in children with NPSLE; and any potential associations with clinical and/or serological markers presenting to a tertiary paediatric rheumatology service. Method: Single centre (Great Ormond Street Hospital NHS Foundation Trust, London) retrospective case series of patients with juvenile NPSLE seen between April 2003 and October 2010. Contrast enhanced brain MR images of the first episode of active NPSLE were reviewed. All patients fulfilled the ACR 1982 revised criteria for the classification of SLE and were classified according to the 1999 ACR case definition for NPSLE syndromes. We excluded patients with a history of alternative neurological conditions. Presenting neuropsychiatric manifestations, immunological findings and treatment are reported. Continuous variables are summarized as median and ranges. Categorical variables are presented as percentages. Fisher's exact test was used to identify the probability of abnormal MRI findings. Results: A total of 27 patients median age 11 (4-15) years, 22 females with suspected juvenile NPSLE were studied. Presenting clinical symptoms included: headaches (85.1%); mood disorder/depression (62.9%); seizures (22.2%); acute psychosis (18.5%); cognitive dysfunction (14.8%); movement disorder (14.8%); acute confusional state (14.8%); aseptic meningitis (7.4 %); demyelinating syndrome (3.7%); myelopathy (3.7%); dysautonomia (3.7%); and cranial neuropathy (3.7%). The principal MR findings were: absence of MRI abnormalities despite signs and symptoms of active NPSLE (59% of all patients); focal hyperintensities on T2-weighted imaging in both white and grey matter (33%); diffuse cortical grey matter lesions (3.7%); and diffuse brain atrophy (18.5%). The presence of>2 neuropsychiatric manifestations strongly associated with abnormal MRI findings (P ¼ 0.014). Positive dsDNA antibodies were noted in 74% of patients; positive extra-nuclear antibodies in 74%, lupus anticoagulant in 15% and aCL antibodies in 37%. All children were treated with HCQ and high doses of i.v. corticosteroids while other treatments used were: i.v. cyclophosphamide (51.8%), rituximab (40.7%) and plasma exchange (11.1%). Conclusion: In the present study, no conventional MRI abnormalities were observed in the majority of patients with clinically active NPSLE. The presence of >2 neuropsychiatric manifestations was strongly associated with abnormal MRI. Improved MR techniques and the advent of other alternative diagnostic imaging modalities may improve the detection rate of brain involvement in juvenile NPSLE. Method: Retrospective analysis of 6-year data from databases of a regional paediatric rheumatology service and the local adult service.
Results: 197 biologic prescriptions were made for CYP (mean age 12.3 years (range 1.4-20.6 years); mean duration 23 months (3-110 months); total 366 patient years). Of these 173 were to 121 patients with JIA or associated uveitis. 64 prescriptions were NICE-approved; the rest (adalimumab 62, Infliximab 21, golimumab 4, anakinra 10, tocilizumab 3, abatacept 5, rituximab 2) required individual funding. There were no differences between non-NICE and NICE-agents in age of onset, or rates of withdrawal for failure of treatment (P ¼ 0.89), adverse events (P ¼ 0.64), or remission (P ¼ 0.72) ( Table 1 ). In general, cost differences from using non-NICE agents were minor, except infliximab. There were significant savings with anakinra in 6 of 9 SoJIApatients.
Conclusion: This large comparison of paediatric and adult services has found no differences in tolerability, efficacy and, in general, cost to support ongoing restriction of biologic use in CYP. New treatment pathways and monitoring will enhance cost:benefit. Disclosure statement: The authors have declared no conflicts of interest. 
